Australia's Firebrick Pharma jumps on publication of its COVID-19 trial results

Firebrick Pharma

02/04/2024 04:07

** Shares of Firebrick Pharma  FRE.AX  rise as much as 6% to
A$0.053, their biggest intra-day pct gain since Feb. 29 
    ** Pharmaceutical firm says the results of its phase 2
COVID-19 trial has been published in Laryngoscope, a journal
highly ranked in the field of otolaryngology
    ** Shares hit their highest level since March 21, with
trading volume 2.5x the 30-day daily avg
    ** Stock was flat this year as of last close, vs a 4%
increase in the benchmark S&P/ASX 200 index  .AXJO 

 (Reporting by Roushni Nair in Bengaluru)
 ((Roushni.Nair@thomsonreuters.com;))